ARID1A mutations are particularly prevalent in gynecologic cancers (detected in 10%–60% of ovarian and endometrial carcinoma cases) [33], especially in premalignant gynecological lesions of endometrioid origin [34]. This evidence concerns the gene ARID1A and endometrial carcinoma.